



BRITISH SOCIETY FOR
ANTIMICROBIAL
CHEMOTHERAPY



AMR MARKET LOUNGE

INTERACTIVE HALF-DAY WORKSHOP

WEDNESDAY 15 NOVEMBER, 0915-1300^{HR}

WELLCOME COLLECTION, EUSTON ROAD, LONDON

PROGRAMME



WELCOME

The AMR Market Lounges are a new venture aimed at providing practical and pragmatic solutions to the challenges AMR poses. This event brings stakeholders together to talk about their needs and what they can offer to the field, and what they can offer to each other. Researchers, scientists, clinicians, funders and industry in the same place, at the same time, on the same platform, looking for linkages, collaborations and solutions. An academic-commercial speed dating arena!

The AMR Market Lounges will provide a unique opportunity to matchmake requirements of researchers and clinicians with the solutions offered by funders, pharma and diagnostic companies. It will not be easy, and there will be challenges, but by participating in a series of dynamic round table discussions delegates can explore and critique what is being offered (be it funding, diagnostics, new treatments) and look at opportunities and barriers for adoption. There will be opportunity to evaluate the wider benefit of the solutions under discussion to both themselves and the wider AMR landscape.

How will this work?

Delegates will participate in six different round table discussions, and come together in a plenary session at the end to share ideas, views and consider what opportunities there are for collaboration across all stakeholder groups. There are suggested discussion topics and questions included in the solution provider biographies – please take these as a guide only, you can raise any relevant issue you wish. The order in which delegates will attend each round table discussion is published against their name on the delegate list.

What can you bring?

The Lounges give you the chance to have those essential conversations, ask the important questions and act to improve AMR within your field. Delegates are asked to bring their experience, details of or ideas for projects they are seeking support, funding or collaboration for, information about any offerings they might have – be it a rapid diagnostic or a research partnership opportunity. Most importantly delegates are asked to arrive with an open mind, ready to think innovatively, strategically and ready to take advantage of what discussion and serendipity might offer.

These are an exciting and essential starting point and platform for moving AMR policy into action and we look forward to welcoming you to contribute to their success.

Philip Howard
President Elect
BSAC

Chris Dowson
Professor of Microbiology
University of Warwick

Scott Buckler
Director
4 All of Us

PROGRAMME

0915 **REGISTRATION AND REFRESHMENTS**

1000 **Welcome and overview of the day**
Phillip Howard, President-elect, British Society for Antimicrobial Chemotherapy & Chris Dowson, Professor of Microbiology, University of Warwick

1015 **Market lounges**
15 minutes per table – 3 minutes introduction and 12 minutes Q&A

MARKET LOUNGE ONE

How can we improve global surveillance of drug resistance and antimicrobial consumption in humans and animals?

Chair: Simon Doherty BVMS CertAqV MRCVS MRQA CBiol FRSB, Junior Vice President of the British Veterinary Association (BVA)

MARKET LOUNGE TWO

How can we reduce the unnecessary use of antimicrobials in aquaculture and their dissemination into the environment?

Chairs: Dan Lee, Standards Coordinator for the Global Aquaculture Alliance (GAA)

MARKET LOUNGE THREE

How can we provide better incentives to promote investment for new drugs and to improve existing ones?

Chair: Dr Shahida Syed, GAMRIF

MARKET LOUNGE FOUR

How can we bring together start-ups and SMEs and keep big pharma interested and investing in the antibiotic pipeline?

Chair: Richard Seabrook, Medicines Discovery Catapult

MARKET LOUNGE FIVE

How can we better support the role of antimicrobial stewardship in our efforts to increase surveillance and drive down antimicrobial consumption?

Chair: Dr Helen Bennett, Momentum Bioscience

MARKET LOUNGE SIX

How can we support One Health objectives of using the right antibiotic, for the right condition and in the right way through improvements and innovations in diagnostic testing and capacity?

Chair: Catherine McLaughlin, NFU Chief Adviser (Animal Health and Welfare) and Deputy Chairman of RUMA (The Responsible Use of Medicines in Agriculture Alliance)

1145 **REFRESHMENTS AND NETWORKING**

1215 **Panel discussion**

1300 **Close**

Zeeshan	Ali	National Policy Officer	Universities Allied for Essential Medicine	1	2	3	4	5	6
Mulu	Assfaw	Nurse	London NorthWest Healthcare NHS Trust	2	3	4	5	6	1
Helena	Azevedo	Senior Lecturer in Biomedical Engineering & Biomaterials	Queen Mary University of London	3	4	5	6	1	2
Frances	Bolt	Research Associate	Imperial College	4	5	6	1	2	3
Daniele	Castagnolo	Lecturer	King's College London	5	6	1	2	3	4
Bilwanath	Chattopadhyay	Consultant Microbiologist (Hon)	DAMA Hospital	6	1	2	3	4	5
Adrian	Coffey	Business Development Manager	Momentum Bioscience	1	2	3	4	5	6
Ron	Dixon	Reader	University of Lincoln	2	3	4	5	6	1
Alexander	Edwards	Associate Professor	University of Reading	3	4	5	6	1	2
Mark	Fielder	Professor of Medical Microbiology	Kingston University/SfAM	4	5	6	1	2	3
Naomi	Fleming	Antimicrobial Pharmacist	Kettering General Hospital	5	6	1	2	3	4
Julie	Fosbrook	Specialist Antimicrobial Technician	Kettering General Hospital	6	1	2	3	4	5
Colette	Gilmore	OPAT Specialist Nurse	Oxord University Hospital FT	1	2	3	4	5	6
Dawn	Hill	OPAT Specialist Nurse	Oxford OUH foundation Trust	2	3	4	5	6	1
Suzanne	Hocknell	Research Associate	Newcastle University	3	4	5	6	1	2
Steve	Holland	Managing Director	Accelerate Diagnostics	4	5	6	1	2	3
Gwen	Knight	Lecturer	Imperial College London / London School of Hygiene and Tropical Medicine	5	6	1	2	3	4
John	Moat	Senior Scientist	University of Warwick	6	1	2	3	4	5
Ian	Morrissey	Director of Business Development	IHMA Europe	1	2	3	4	5	6
Louise	Norton-Smith	Head of International AMR	GAMRIF Fund	2	3	4	5	6	1
Andrew	Pearson	Royal Marsden Patient Governor	BSAC, Royal Marsden Patient Hospital	3	4	5	6	1	2
Renee	Piovanelli	Product Manager	Point of Care Testing Ltd	4	5	6	1	2	3
Partha	Ray	Lecturer Dairy Animal Science	University of Reading	5	6	1	2	3	4

Liam	Shaw	PhD student	UCL	6	1	2	3	4	5
Dale	Shelton	Director	OpGen / AdvanDx	1	2	3	4	5	6
Suzi	Shingler	Campaign Manager	Alliance to Save our Antibiotics	2	3	4	5	6	1
Josh	Sisskin	Head of the GAMRIF fund	GAMRIF Fund	3	4	5	6	1	2
Lee	Slater	Snr. Policy Advisor – AMR in the Environment	Defra	4	5	6	1	2	3
Angkana	Sommanustweechai	PhD candidate	London School of Hygiene and Tropical Medicine	5	6	1	2	3	4
Emilie	Taymor	Associate Director, outcomes research	MSD	6	1	2	3	4	5
Sumi	Thaker	Chief Executive Office	Momentum Bioscience	1	2	3	4	5	6
Anita	Toscani	Research Fellow	King's College London	2	3	4	5	6	1
David	Wareham	Senior Clinical Lecturer / Honorary Consultant in Microbiology	Queen Mary University London / Barts Health NHS Trust	3	4	5	6	1	2
Maria	Yousif	Clinical Commissioning Pharmacist	NHS Lambeth CCG	4	5	6	1	2	3

Christopher	Dowson	Professor of Microbiology	University of Warwick	Co-Chair
Phillip	Howard	President Elect	British Society for Antimicrobial Chemotherapy	Co-Chair
Simon	Doherty	Junior Vice President	British Veterinary Association	Solution provider: Roundtable 1
Dan	Lee	Standards Coordinator	Global Aquaculture Alliance	Solution provider: Roundtable 2
Shahida	Syed	Research and Science Project Coordinator	Global Health Security Programme, Department of Health	Solution provider: Roundtable 3
Richard	Seabrook	Senior Advisor	Medicines Discovery Catapult	Solution provider: Roundtable 4
Helen	Bennett	Market Development Manager	Momentum Bioscience	Solution provider: Roundtable 5
Scott	Buckler	Director	4 All of us	Facilitator
Michael	Corley	Senior Policy and Public Affairs Officer	British Society for Antimicrobial Chemotherapy	Facilitator
Tracey	Guise	Chief Executive Officer	British Society for Antimicrobial Chemotherapy	Facilitator

BSAC AND 4 ALL OF US ARE GRATEFUL FOR THE SUPPORT PROVIDED BY:

British Veterinary Association



British Veterinary Association

One Health is the integrative effort of multiple disciplines working locally, nationally, and globally to attain optimal health for people, animals, and the environment. The British Veterinary Association (BVA) have a significant interest in One Health and, on the back of the joint BVA / Royal College of Veterinary Surgeons (RCVS) Vet Futures initiative, established a UK One Health Coordination Group - along with a range of stakeholders representing medical, nursing, veterinary, public health and environmental interests - to champion excellence in this field. Naturally, this includes exploring novel approaches to the surveillance of diseases and of drug resistance, to the use of existing antibiotics, and to developing the pipeline for new antibiotics and non-antibiotic alternatives. BVA is delighted to have the opportunity to take part in this BSAC workshop and we look forward to sharing ideas with other delegates

Simon Doherty is the Junior Vice-President of the British Veterinary Association (BVA). His veterinary career has spanned progressive farm animal practice, research, diagnostics and surveillance, business development and consultancy. He is the Animal Science & Aquaculture Specialist for the UK Government Department for International Trade, has been an author on many peer-reviewed publications and reports in the animal health space; covering topics as diverse as vaccine design, rapid diagnostics, bovine mastitis, emerging & re-emerging diseases of livestock and salmonid feed additives and is a past-president of the North of Ireland Veterinary Association (NIVA) and of the Northern Ireland Branch of the BVA.

MARKET LOUNGE ONE

How can we improve global surveillance of drug resistance and antimicrobial consumption in humans and animals?

Chair: Simon Doherty BVMS CertAqV MRCVS MRQA CBiol FRSB, Junior Vice President of the British Veterinary Association (BVA)

Discussion topic and questions: *Tackling drug resistance requires an integrative effort across all sectors, human, animal (companion and husbandry) and there is a need to better combine the efforts of all sectors to reduce AMR. Where do you see the opportunities for a shared agenda in relation to surveillance of disease, antibiotic use and antibiotic development?*

Global Aquaculture Alliance



Dan Lee is the standards coordinator for the Global Aquaculture Alliance's Best Aquaculture Practices (BAP) third-party certification programme. As standards coordinator, Lee manages the 12-member Standards Oversight Committee (SOC) and various technical committees that contribute to the development of the BAP standards for seafood processing plants, farms, hatcheries and feed mills. He was instrumental in the BAP standards being recognized by the Global Sustainable Seafood Initiative (GSSI) and Global Food Safety Initiative (GFSI). Lee is also a research officer for the Centre for Applied Marine Sciences at Bangor University, where his main interests lie in aquaculture systems with minimal environmental impacts. A graduate of Bangor University and the University of York, Lee has years of aquaculture experience with an expertise in design, implementation and project management.

Dan will give an overview of the role of antibiotics in commercial finfish and shellfish farming worldwide and talk about the difference between responsible and irresponsible antibiotic use in aquaculture. Restrictions on antibiotic use are addressed in great detail in the BAP finfish and crustacean farm standards, which require that antibiotics be used with veterinary oversight and only for therapeutic purposes for the control of diagnosed diseases and not for prophylactic purposes. There is also an antibiotics testing protocol included in both the BAP finfish and crustacean farm standards and BAP seafood processing plant standards. In addition to its BAP program, the non-profit GAA is involved in various pre-competitive education and advocacy activities in the global seafood arena, including an annual conference, online magazine, e-learning program, online community, film initiative and membership.

MARKET LOUNGE TWO

How can we reduce the unnecessary use of antimicrobials in aquaculture and their dissemination into the environment?

Chair: Dan Lee, Standards Coordinator for the Global Aquaculture Alliance (GAA)

Discussion topic and questions: *The BAP finfish and crustacean farm standards are an important measure in leveraging change and securing appropriate antibiotic use in aquaculture. Are there lessons and benefits from the certification approach that can be applied to other sectors?*

The Department of Health



Department of Health

The Department of Health, helping people to live better for longer.

The Global AMR Innovation Fund, supporting international investment for AMR research and development for the benefit of people in low and middle income countries.

MARKET LOUNGE THREE

How can we provide better incentives to promote investment for new drugs and to improve existing ones?

Chairs: Dr Shahida Syed, GAMRIF

I'm the Research and Science Project Coordinator of the Global AMR Innovation Fund (GAMRIF) at the UK Department of Health. I'm interested in understanding the global funding and research landscape of AMR from a One Health perspective, and making links with stakeholders in all sectors and disciplines to better understand the knowledge gaps and needs to tackle AMR. Prior to joining DH, I carried out a postdoc at the University of Edinburgh, where I was developing an isothermal nucleic acid amplification technology for molecular diagnostic applications for AMR. I also worked as R&D scientist at Relitect Ltd. developing an electrochemistry-based sensing assay for small molecule detection.

Discussion topic and questions: *Innovative approaches to R&D are essential in successfully addressing AMR and maintaining the antibiotic pipeline and ensuring equitable access to new medicines by all. How can GAMRIF and likewise funding initiatives best furnish this need?*

The Medicines Discovery Catapult



The Medicines Discovery Catapult is a national centre of expertise for the discovery and early stage development of medicines. We are an independent not-for-profit company funded by Innovate UK to actively support innovation and help remove obstacles to progress. We do this by encouraging collaboration across the UK's medicines R&D community.

MARKET LOUNGE FOUR

How can we bring together start-ups and SMEs and keep big pharma interested and investing in the antibiotic pipeline?

Chair: Richard Seabrook PhD, MBA, Medicines Discovery Catapult

Discussion topic and questions: *The challenges faced by those seeking to discover and embark on early development of new medicines are immense, and can be considered to far outweigh the opportunities in the field. What do you need / what is needed to help transform ideas into commercial products and services and how can the key obstacles to progress in the discovery and early stage development of antibiotics be overcome?*

Momentum Bioscience

Momentum is developing a range of innovative diagnostic products to help combat antibiotic resistance and sepsis by providing early detection of the presence and absence of bloodstream infections. Up to 90% of patients suspected of sepsis are administered IV antibiotics and are confirmed negative for a bloodstream infection at 5-days. Momentum's core ETGA® technology allows universal detection of viable organisms which can allow the early reporting of negative blood cultures, from patients suspected of sepsis, on day 1 instead of day 5 with an NPV of 99.5% - thus reducing the over use of unnecessary antimicrobials.

MARKET LOUNGE FIVE**How can we better support the role of antimicrobial stewardship in our efforts to increase surveillance and drive down antimicrobial consumption?**

Chair: Dr Helen Bennett, Momentum Bioscience

Discussion and questions: *Tackling drug resistance isn't just about rapid ID of positive infections to focus the correct antimicrobial quickly. It is also about getting patients off empirical antimicrobials quickly, especially in those who don't have a bloodstream infection. This can account for up to 90% of suspected sepsis cases. Where do you see the challenges when it comes to the overuse of antimicrobials? What are your specific challenges in a hospital setting?*

National Farmers Union (NFU)



The NFU is the largest agricultural trade organisation in the UK. We represent around 46,000 farmer and grower members, championing British farming and providing professional representation and services to those members. In 1997, the NFU, alongside the BVA, and pharmaceutical sector, came together to create RUMA with the aim of promoting the highest standards of food safety, animal health and animal welfare in the British livestock industry. For the last year, RUMA has been working with farmer and veterinary experts from the main farmed livestock sectors (including game and aquaculture) to meet a UK Government commitment to reduce antibiotic use in food production to a multi-species average of 50 mg/kg by 2018. Through collaborative efforts, RUMA has exceeded that challenge, 2 years early. The UK farmed animal sector has reduced antibiotic use by 27% and is sitting now at a multi-species average of 45mg/kg based on 2016 sales figures.

MARKET LOUNGE SIX

How can we support One Health objectives of using the right antibiotic, for the right condition and in the right way through improvements and innovations in diagnostic testing and capacity?

Chair: Catherine McLaughlin, NFU Chief Adviser (Animal Health and Welfare) and Deputy Chairman of RUMA (The Responsible Use of Medicines in Agriculture Alliance)

Catherine has a degree in agricultural animal science from Aberdeen University and a post graduate diploma in farm business organisational management from the Scottish Agricultural College (now the SRUC). She's worked for the National Farmers' Union (England and Wales) since 2006, and has the strategic policy lead for animal health and welfare across all farmed animal species. She's represented UK and EU farmers in EU Expert panels on AMR, and sits on various high-level strategy groups for exotic and endemic disease control within Defra. She represents the NFU on the RUMA Board, is the Deputy Chairman of RUMA, and Chairs the RUMA independent scientific group.

Discussion and questions: *RUMA, and its partner organisations, are working to 'Reduce, Refine and Replace' HP-CIA antibiotics in the farmed food sector across the UK, but a lack of 'fit for purpose' diagnostics have the potential to hold back our efforts. How do we make diagnostics available, accessible, effective and practical for use on the ground, in both a human or veterinary capacity?*



BRITISH SOCIETY FOR
**ANTIMICROBIAL
CHEMOTHERAPY**

53 Regent Place, Birmingham, B1 3NJ

www.bsac.org.uk

+44 (0)121 236 1988



Suite 3a, Bowden Hall, Bowden Lane,
Marple, Stockport, SK6 6NE

4allofus.org.uk

0161 4845680